Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths in the United States. The deoxynucleoside analog gemcitabine is among the most effective therapies to treat PDAC; however, nearly all patients treated with gemcitabine either fail to respond or rapidly develop resistance. One hallmark of PDAC is a striking accumulation of stromal tissue surrounding the tumor, and this accumulation of stroma can contribute to therapy resistance. To better understand how stroma limits response to therapy, we investigated cell-extrinsic mechanisms of resistance to gemcitabine. We show that conditioned media from pancreatic stellate cells (PSC), as well as from other fibroblasts, protects PDAC cells from gemcitabine toxicity. We find that the PSC conditioned media protective effect is mediated by secretion of deoxycytidine, but not other deoxynucleosides, through equilibrative nucleoside transporters.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is notorious as a cancer with poor therapeutic options for most patients. Few patients with PDAC are eligible for surgery, and systemic therapies are all limited in their benefit. FOLFIRINOX combination therapy (Folinic acid, 5-fluorouracil, irinotecan and oxaliplatin) is the most effective regimen for patients who can tolerate the significant side effects. Gemcitabine also can be effective in some patients and has more tolerable side effects (1) . Regardless of which therapy is used, the 5-year survival rate is only 8.5%, and, due to increasing incidence, PDAC is projected to become the second leading cause of cancer deaths by 2030 (2, 3) .
One striking feature of PDAC is a significant accumulation of stiff stromal tissue surrounding the tumor, termed the desmoplastic response, and this has been proposed as one factor that makes this cancer so resistant to therapy (4) (5) (6) . Initially, the stiff stroma was thought to present a physical barrier to drug perfusion, however it is now appreciated that limiting drug delivery is not the only reason pancreatic tumors are therapy resistant (6) (7) (8) . The ways in which the stromal cells within pancreatic cancer contribute to PDAC resistance has become an area of intense study, with a recent focus on interaction between stroma and PDAC via direct contact and paracrine signaling (9) (10) (11) (12) . A variety of biomolecules secreted by pancreatic stromal cells have been implicated in resistance to radio-and chemotherapy, including cytokines such as SDF-1a
and IGFs, extracellular matrix (ECM) proteins such as fibronectin and collagen I, and even exosomes (13) (14) (15) (16) (17) .
In addition to the above methods, the stroma has also been shown to cause resistance by sequestering gemcitabine, a deoxycytidine (dC) analog (11, 18) . The mechanism by which gemcitabine causes toxicity in cells in well studied (19) . This drug enters cells through a variety of nucleoside transporters (20) . Once inside cells, gemcitabine is activated via phosphorylation by deoxycytidine kinase to form the active gemcitabine-triphosphate, which can be incorporated into DNA in place of dCTP resulting in masked chain termination, DNA damage, and apoptosis (21) .
Here, we show that PSCs, a pancreatic stromal cell type, secrete dC through equilibrative nucleoside transporters. In turn, deoxycytidine protects PDACs from gemcitabine toxicity. We show that dC-mediated gemcitabine resistance likely acts at the level of competition for deoxycytidine kinase. Several other fibroblast cell lines also secrete dC, and media conditioned by PSCs cause resistance to other dC analogs as well as deoxyadenosine analogs. Targeting this stromal dC production and secretion may represent an opportunity to improve the efficacy of nucleoside analog therapies. (22) . PSC, PSC1, and PSC3 cells were derived from the pancreas of FVB/nj mice upon induction of pancreatitis via caerulein treatment mice as described (23, 24) . In brief, mice were injected with 8 hourly injections of 50µg/kg of caerulein for two consecutive days. Mice were housed animal research facilities of the MIT Division of Comparative Medicine (DCM). All facilities are fully accredited by the AAALAC (Animal Welfare Assurance number A-3125) and meet NIH standards as set forth in the "Guide for Care and Use of Laboratory Animals" (DHHS). The MIT DCM Committee on Animal care last reviewed and approved the planned research in this proposal for the Hemann lab (Protocol Number 0515-044-18) on 4/12/18. After the last injection, pancreata were dissected and minced into 2-3 mm pieces which were cultured in a 10 cm dish in 10 mL of DMEM:F12 medium supplemented with 2 mM glutamine and 15% fetal bovine serum. After 72 hours, tissue pieces were removed and the PSCs were immortalized by transduction with SV40. The infected population was selected by puromycin treatment at 2 µg/mL. PSC6 cells were derived from the pancreas of C57BL/6J mice via density centrifugation as previously described (25) , and were immortalized as described above. 293T cells were purchased from ATCC. Hepatic stellate cells (HSC) were a gift from Dr.
Materials and Methods

Cell
Linda Griffith (MIT). Primary and immortalized MEFs were isolated and cultured as previously described (24) . Cell lines were maintained in DMEM (Corning) supplemented with PenicillinStreptomycin (Corning), 2mM L-glutamine (Corning), and 10% FBS (HyClone) and routinely tested for mycoplasma contamination using MycoAlert (Lonza).
Conditioned Media
Conditioned media (CM) was produced by changing culturing media of 70%-90% confluent plates, then collecting the media after the indicated number of days passed. CM was filtered through a 0.2 µM SFCA membrane (Corning). Unless otherwise noted, cells conditioned the media for three days prior to collection, and CM was used at a 1:5 dilution. When not in use, CM was stored at -20°C. Boiled CM was incubated at 100°C for 1 hour and centrifuged to remove precipitate. Proteinase K digested CM was incubated with 2 g/mL proteinase K (Invitrogen) for 1 hour at 37°C. Proteinase K was inactivated at 95°C for 10 minutes and the digested media was centrifuged to remove precipitate. Size cutoff columns (EMD Millipore) were used to filter out all compounds larger than 3kDa from the media.
Chemicals
Gemcitabine, azacytidine, and decitabine were purchased from LC Labs. Fludarabine, azidothymidine, and cladribine were purchased from Tocris. Cytarabine was purchased from Selleck Chemicals. Puromycin, nucleosides, nucleotides, and dCTP isotope were purchased from Sigma. Isotopes of deoxycytidine, deoxythymidine, deoxyguanosine, and deoxyadensoine were purchased from Cambridge Isotope Laboratories. Deoxyuridine isotope was purchased from Santa Cruz. Cytarabine, decitabine, azidothymidine, and azacytidine were dissolved in DMSO (Sigma) at 50-100mM and stored at -80°C until use. Working stocks were diluted to 5mM in 100% ethanol (VWR) and stored at -20°C until use. Fludarabine and Cladribine were dissolved in DMSO at 50mM, then divided to 100 µL aliquots. Aliquots were stored at -80°C. Aliquots were diluted in DMSO to 5mM and divided to 10 µL aliquots and stored at -20°C, to reduce freeze/thaw cycles. Puromycin was dissolved in sterile water at 50mM and stored at -20°C.
Gemcitabine was dissolved in DMSO at 10mM and stored at -20°C. Nucleosides were dissolved in sterile water at 10mM and stored at -80°C. Nucleoside and nucleotide isotopes were dissolved in HPLC-grade water (Sigma) at 1mM and stored at -80°C.
Cell Viability Assay
Cells were seeded in cell-culture treated 384-well plates (Falcon) in triplicate and spun for 5 minutes at 1500 RPM then allowed to attach for 4-6 hours. After attachment, cells were treated as indicated. Cell viability was measured after 72 hours using resazurin sodium salt (Sigma).
Resazurin was used at 0.167 mg/mL and plates were analyzed 3-4 hours after addition.
Fluorescence was measured using the Tecan M200 Pro at an excitation of 550nm and emission of 600nm. GR50 values were calculated using GraphPad Prism 5. µL HPLC grade chloroform (Sigma-Aldrich). Samples were vortexed for 10 minutes at 4 °C, then centrifuged at 21000 x g at 4°C for 10 minutes. 400 µL of the aqueous layer was removed and dried under nitrogen.
Metabolite Extraction
HPLC fractionation
Conditioned media was extracted as described above, then the dried, aqueous layer was 
LC/MS
Dried media and cell extracts were resuspended in 100 µL HPLC grade water. LC/MS analysis was performed using a QExactive orbitrap mass spectrometer using an Ion Max source and heated electro-spray ionization (HESI) probe coupled to a Dionex Ultimate 3000 UPLC system (Thermofisher). External mass calibration was performed every 7 days. Samples were separated by chromatography by injecting 10 µL of sample on a SeQuant ZIC-pHILIC 2.1 mm x 150 mm voltage was set to 3.0 kV, the heated capillary held at 275˚C, and the HESI probe was held at 350˚C. The sheath gas flow rate was 40 units, the auxiliary gas flow was 15 units and the sweep gas flow was one unit. The MS data acquisition was performed in a range of 70-1000 m/z, with the resolution set at 70,000, the AGC target at 1x10 6 , and the maximum injection time at 20 msec. Relative quantitation of polar metabolites was performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) using a 5 ppm mass tolerance and referencing an in-house library of chemical standards. For analysis of deoxynucleoside and dCTP concentrations in conditioned media, peak areas were compared to stable isotope labeled internal standard peak areas to calculate concentration. For analysis of intracellular metabolite concentrations, peak areas were normalized using 13 C stable isotope labeled internal standards and intracellular concentrations were calculated using measurements of total cell volume made using a Coulter counter.
Statistical Analysis
Statistics were performed using GraphPad Prism 5 (GraphPad Software Inc). All error bars represent standard error of the mean.
Results
PSCs secrete a small molecule that protects PDAC cells from gemcitabine toxicity
To better understand tumor microenvironmental contributions to gemcitabine resistance in PDAC, we extracted activated PSCs via the outgrowth method as previously described (23, 24) .
We conditioned media (CM) in the presence of these PSCs for varying times and then examined gemcitabine dose responses on PDAC cells in the presence of varying dilutions of this CM (Fig.   1A ). Media conditioned by the PSCs for 3 days conferred 11-fold increase in the dose of gemcitabine required to achieve 50% reduction in the growth rate of PDAC cells (GR50, a metric which takes into account cytostatic and cytotoxic effects of a pertubation) (25) . Further, this protective effect was present even in highly diluted CM, with 5% CM conferring 2-fold increase in GR50 (Fig. 1B) . The protective effect accumulated in the CM over time, conferring almost 100-fold increase in gemcitabine GR50 after 9 days of media conditioning (Fig. 1C) . The CM also did not affect the proliferation of PDAC cells in the absence of gemcitabine. To begin to characterize the activity in conditioned media that is responsible for this effect, we incubated the CM at 100°C for 1 hour, digested the CM with proteinase K, and tested the flow through of CM passed through a 3 kDa cutoff filter. The protective effect of the CM was retained even after boiling, proteinase K exposure, or passage through a filter to deplete high molecular weight material, implicating a small metabolite as the likely cause of the protective effect (Fig. 1D) . Fig. 2A) .
Deoxycytidine accumulates in PSC conditioned media
To identify the activity responsible for the protective effect observed in HPLC fraction 4, we used liquid chromatography/mass spectrometry (LC/MS) to assess the abundance of 150
common plasma metabolites present in HPLC fraction 4 from PSC CM, 293T CM, and regular non-conditioned media (RM). Of these metabolites, deoxycytidine (dC) and acetylalanine were the only compounds present in higher quantities in fraction 4 of PSC CM compared to the equivalent fraction from 293T CM and RM (Fig. 2B) . N-acetyl alanine was unable to protect PDAC cells from gemcitabine toxicity at doses up to 50 µM (Fig. S1A) , so we focused our analysis on dC. Interestingly, after three days in culture, dC in PSC CM accumulated to 21.3 µM compared to 0.18 µM in RM and 6.4 µM in 293T CM (Fig. 2C) , suggesting that PSCs may be exporting deoxycytidine into the media.
Deoxycytidine is sufficient to protect PDAC cells from gemcitabine toxicity
To determine if dC or other nucleosides are sufficient to protect PDAC cells from gemcitabine toxicity, we conducted dose response curves with each nucleoside in the presence or absence of 0.025 µM gemcitabine, a dose that kills 100% of PDAC cells after 3 days in the absence of CM.
Of all five nucleosides tested, only dC protected PDAC cells from gemcitabine toxicity, with a GR50 of 0.46 µM confirming the sufficiency of dC to cause the protective phenotype (Fig. 2D) .
PSCs do not produce substantial quantities of other nucleosides
While only dC protected PDAC cells from gemcitabine toxicity, we asked if PSCs secrete other nucleosides as well. Using LC/MS, levels of thymidine, deoxyuridine, dC, deoxyguanosine, and dCTP were quantitated in 3-day PSC CM as well as in metabolite extracts of PSC cells. We confirmed high levels of dC secretion into the media, and also observed high levels of intracellular dC at 88 µM. PSCs contained detectable levels of thymidine and deoxyuridine with some release into the media albeit at lower levels than dC. Deoxyguanosine (dG) was detected in cells, but not in the media. dCTP was also only detected in cells and not in the media (Fig.   3A,B) .
PSC conditioned media does not prevent gemcitabine from entering PDAC cells
Gemcitabine is transported into cells via the same nucleoside transporters that transport dC (21).
Thus, we hypothesized that the dC present in the PSC CM may compete with gemcitabine for these transporters, blocking gemcitabine from entering the cell. We treated PDAC cells with 0.1 µM gemcitabine, 50 µM gemcitabine (representative of patient plasma concentration achieved after infusion (26)), and/or diluted PSC CM for two hours. We then quantified intracellular gemcitabine levels, as well as thymidine, deoxyuridine, dC, deoxyguanosine, and dCTP using LC/MS. Interestingly, treatment with PSC CM did not affect intracellular gemcitabine levels at either dose tested, suggesting that deoxycytidine competes with gemcitabine downstream of uptake via nucleoside transporters (Fig. 3C) . Similarly, gemcitabine treatment did not affect import of dC or other nucleosides from PSC CM into PDAC cells ( Fig. S1B-E) . Treatment with PSC CM did rescue intracellular dCTP levels after treatment with 50 µM gemcitabine, suggesting that PSC CM is able to protect cells from gemcitabine toxicity even at this high physiologic dose (Fig. 3D) .
Inhibiting equilibrative nucleoside transporters on PSCs reduces deoxycytidine in conditioned media
We hypothesized that the PSCs were secreting large quantities of dC through equilibrative nucleoside transporters (ENTs) which have previously been shown to transport dC (20) . Indeed, when we treated PSCs with a non-toxic dose of two different ENT inhibitors (Fig. S2A) , the final concentration of deoxycytidine in the CM from these cells was reduced to a level similar to that in 293T CM (Fig. 4A, Fig. S2B ). Treatment with ENT inhibitors did not effect levels of other nucleosides secreted by PSCs (Fig. S2 C-D) . Gemcitabine can be transported into PDAC cells through the same transporters and we were unable to inactivate ENT inhibitors by boiling the CM (Fig. S3) , likely explaining why ENT inhibitor treatment did not completely abolish the ability of PSC CM to protect cancer cells from gemcitabine toxicity (Fig. 4B) .
Some other fibroblast cell types also secrete deoxycytidine
In order to determine if this protective effect is specific to PSCs, we analyzed CM from several additional PSC cell lines isolated with different methodologies or from different mouse background (PSC1, PSC3, PSC6), mouse embryonic fibroblasts (MEFs), and hepatic stellate cells (HSCs). We found that CM from the additional PSC cell lines and MEFs did protect PDAC cells from gemcitabine toxicity to varying degrees. However, HSC CM did not protect PDACs from gemcitabine toxicity (Fig. 5A ), suggesting secretion of deoxycytidine is not unique to
PSCs, but not all fibroblast cell types secrete deoxycytidine.
PSC conditioned media protects PDACs from other nucleoside analog drug toxicity
Other nucleoside analogs are active chemotherapy agents, and we conducted dose response curves to determine if the PSC CM can protect against other nucleoside analog toxicity. As expected, diluted PSC CM provided 2-fold increase in GR50 to the deoxycytidine analogs cytarabine and decitabine. Interestingly, the CM also caused a 2-fold increase in GR50 to deoxyadenosine analogs fludarabine and cladribine. Toxicity of the cytidine analog azacytidine and the thymidine analog azidothymidine were not affected by the CM (Fig. 5B) . These data suggest that production of dC by resident fibroblasts might contribute to cancer resistance to some nucleoside analog chemotherapies.
Discussion
Our results add deoxycytidine to the arsenal of molecules secreted by pancreatic stroma that contribute to chemotherapy resistance in PDAC. Deoxycytidine does not hinder gemcitabine entry into cells, suggesting competition for downstream processing enzymes such as deoxycytidine kinase. Deoxycytidine secretion may be a conserved phenotype of some types of fibroblasts, as MEF CM was able to protect PDAC cells from gemcitabine toxicity, albeit to a lesser extent. However, the lack of dC secretion by hepatic stellate cells suggests this is not a property of all fibroblasts and other factors might influence whether these support cells produce this molecule.
While PSC CM did not protect PDAC cells from azacytidine or azidothymidine toxicity, it did confer protection against cytarabine, decitabine, fludarabine, and cladribine. Neither azacytidine nor azidothymidine rely on deoxycytidine kinase for processing into their toxic forms, but cytarabine, decitabine, fludarabine, cladribine, and gemcitabine are all phosphorylated by deoxycytidine kinase into their toxic forms (27, 28) . This distinction further supports the hypothesis that nucleoside analog toxicity inhibition by deoxycytidine acts at the level of deoxycytidine kinase (Fig. 5C ).
We observed that the high levels of PSC nucleoside production and secretion were limited to specifically deoxycytidine. Although we were unable to measure deoxyadenosine levels, deoxyguanosine was at a low concentration in PSCs, and was undetectable in PSC CM. This potential pyrimidine specificity suggests that the mechanism of deoxycytidine production is not due to general upregulation of nucleoside production. Deoxycytidine secretion is a known mechanism of maintaining intracellular dCTP pool sizes when too much is being produced (29) (30) (31) . Therefore, the deoxycytidine production and secretion specificity also suggests that PSCs may have increased levels of dCTP production perhaps as a biproduct of another metabolic process, and excess dCTP is converted into deoxycytidine and secreted.
The deoxycytidine specificity further suggests that the PDAC microenvironment may have a high level of deoxycytidine. At first glance this seems paradoxical -the microenvironment of PDAC is specifically protective against one of the only drugs effective for this tumor type, and which is one of only a small number of malignancies in which this drug is used (1, 26) . We 
